Clinical and phamacological analysis of Sars Cov 2: how combination
therapy makes checkmate
Abstract
Objectives:Literature data have shown that decreasing the
SARS-CoV-2-induced hyperinflammatory state is essential for fighting the
virus in an emergency and avoiding death. Many authors have divided the
SARS-CoV-2 infection into three phases, of which the second and third
are purely inflammatory. For this reason, while the development of
antiviral drugs and vaccines is increasing, the best pharmacological
goal is the decrease in proinflammatory molecules. Design: In phase 3,
the most serious, there is an overdrive state of the immune system with
consequent assault against all tissues and lung damage. Sars cov 2
pneumonia is characterized by “cytokine storm” and can lead to death.
Acting in advance and with combination therapy aimed at blocking the
inflammatory cascade can be effective. Results: Many drugs are being
tested in evaluating these effects such as IL-6 or IL-1 inhibitors,
chloroquine / hydroxycloroquine and colchicine which is proving its
effectiveness especially in association in the last two stages of
SARS-CoV-2 infection. modulating the inflammatory state and allowing to
use an effective combined terepia with drugs at non-lethal dosages.
Colchicine is considered safe and effective for the treatment and
prevention of the cytokine storm in patients suffering from SARS-CoV-2
infection and is certainly an added remedy to other therapeutic agents
with a safety profile superior to that provided by others. drugs.
Conclusion:The aim of this study is to explain the pharmacological
rationale behind the use of a combination therapy as an effective and
safe remedy to decrease pneumonia and the consequent death from Sars CoV
2.